A subsidiary of Johnson & Johnson (NYSE:JNJ) has filed a New Drug Application to the Food and Drug Administration for a combination treatment for type 2 diabetes, according to a company press release.

The treatment is a combination of an experimental medication, canagliflozin, and an established drug, metformin. Combined in a pill, the treatment is intended for patients with type 2 diabetes. This is a form of the disease in which either the body doesn't respond correctly to insulin or doesn't produce enough of the substance.

The new drug has been developed by Johnson & Johnson's Janssen Research and Development subsidiary.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.